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Abstract
In this chapter we aim at presenting the state of the art in liver surgery. After 
a brief introduction about natural evolution of hepatocellular carcinoma (HCC) 
either in cirrhotic or non-cirrhotic patients, this manuscript will focus on planning 
and timing surgery: CT evaluation of the remnant liver; biopsy and ultrasonogra-
phy (US) evaluation of liver disease; intraoperative US; surgical techniques, such 
as major and limited hepatectomies and two-stage hepatectomies, each of them in 
open or mini-invasive approach; and their possible complications. Follow-up and 
further interventions during expected recurrences will be highlighted. Our chapter 
will also treat topics such as patient’s quality of life, importance of multidisciplinary 
evaluation and the role of surgeon in it.
Keywords: HCC, liver cirrhosis, liver surgery, open surgery, laparoscopic liver 
surgery, robotic liver surgery, HCC management, HCC follow up,  
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1. Introduction
Hepatocellular carcinoma (HCC) accounts for about 75–85% of primary liver 
malignancy. Being the most common histotype of liver cancer, it contributes signifi-
cantly to global disease and mortality. Liver cancer ranks sixth for worldwide incidence 
and third for worldwide mortality. In Europe it ranks 14th for incidence and 8th for 
mortality [1]. In cirrhotic patients it remains one of the major causes of death [2, 3].
HCC incidence is worldwide heterogeneous because of the distribution of its 
main risk factors: hepatitis B, hepatitis C, alcoholic hepatitis, non-alcoholic fatty 
liver disease (NAFLD) and steatohepatitis (NASH) (Table 1) [4] chronic liver 
disease is the main background in which HCC arises (70–90% of all patients) [2]. 
It usually develops in cirrhotic liver, even if 10–20% of cases involve patients not yet 
cirrhotic [3]. These ones tend to receive a late diagnosis, due to the lack of symp-
tomatology in early stage and/or inadequate surveillance [3].
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Clinical evaluation and multidisciplinary approach are fundamental to submit 
patients to the most appropriate treatment. Assessment must consider patients’ 
characteristics (general conditions, performance status, physiological age, life expec-
tancy, treatment tolerability), HCC stage, oncological principles and liver status [4].
Several approaches, both surgical and non-surgical, are available for HCC treat-
ment. Surgery is the first-line treatment in terms of overall survival and disease-
free survival [5].
Surgical approaches include liver resections (LRs) and liver transplantation (LT).
LR is the gold standard in non-cirrhotic liver, whereas cirrhotic patients should 
be properly selected because of higher risk of complications [5].
LT allows radical tumor removal (R0) combined with the cure of underlying 
liver disease [6]. It is the treatment of choice in patients unsuitable for resec-
tive surgery that fall within the Milan criteria [5]. LT is indicated in patients 
≤65 years (extended to 70 and 70+ patients, in some cases) [7] with severe 
cirrhosis (MELD > 15). According to the Milan criteria, patients should have 
a single nodule ≤5 cm or up to three nodules measuring ≤3 cm [8, 9], with no 
macroscopic vascular invasion nor extrahepatic metastases [5, 9]. After some 
years of experience, the Milan criteria were extended, developing up-to-seven 
criteria, in which patients are considered eligible for liver transplant when the 
sum of the size (in cm) of the largest tumor and the number of lesions is ≤7, in 
the absence of microscopic vascular invasion [10]. Up-to-seven criteria should be 
used carefully because overall survival decreases as the number and size of tumor 
grows [11]. This principle is called “Metro ticket” [12]. Because of organs’ low 
availability, lower recurrence risk patients shall be selected for transplantation 
in order to optimize organ allocation [12]. Resection and noninvasive therapies 
could be performed to control lesion progression during waiting period (bridg-
ing) or in order to downstage HCC [5, 6]. Liver function in waiting list is com-
monly evaluated through Child-Pugh (CTP), MELD and MELD-Na scores [13]. 
The latter is a good predictor of waitlist mortality in cirrhotic patients, so it shall 
be taken into account to improve organ allocation system [14]. Pretransplant 
mortality rate in liver malignancy accounts for about 10 deaths per 100 patient 
years of waiting [15].
Non-surgical approaches include percutaneous radiofrequency thermoablation 
(RFA), microwave thermoablation (MWA), drug-eluting bead transarterial chemo-
embolization (DEB-TACE), transarterial radioembolization (TARE), percutaneous 
ethanol injection (PEI), cryoablation and laser ablation (LA). Except from ther-
moablations, which are considered curative in small lesion (≤2 cm), non-surgical 
approaches are commonly palliative [16]. Elderly, very elderly and frail patients, 
either at presentation or in the case of recurrences, may benefit from these tech-
niques in terms of survival and quality of life [4].
RFA and MWA are the most appropriate treatment in patients with BCLC 0 and 
A tumors not eligible for surgery [5, 17]. RFA induces coagulative necrosis in tumor 
Parameter Mean incidence in cirrhotic liver Mean incidence in non-cirrhotic liver
HBV 41.65% 30.60%
HCV 44.18% 14.36%
Alcoholic hepatitis 30% 21.77%
NAFLD-NASH 6.48% from a single study 6.45% from a single study
Desai et al. [3].
Table 1. 
HCC incidence in cirrhotic and non-cirrhotic patients per risk factor.
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cells and in a “safety ring” of peritumoural tissue using frictional heat generated by 
high-frequency alternating current. Lesions adjacent to the vessels and biliary tree 
or in subcapsular positions could compromise RFA effectiveness and safety  
[5, 18, 19]. However, microwave ablation has been recognized as effective in this 
kind of lesions, due to damage concentration and less heat dispersion [17, 20]. MWA 
uses electromagnetic energy to induce a larger necrotic area than RFA thanks to 
faster heating and higher temperature [17]. Overall, RFA and MWA provide similar 
results in terms of local control and survival rates [17].
DEB-TACE induces tumor necrosis through intraarterial delivery of micro-
spheres fulfilled with chemotherapic drug that may vary in size and chemothera-
pic agent to treat different types of HCC [21]. This technique profits from the 
presence of a singular artery feeding the tumor. TACE is a palliative treatment 
indicated in patients not eligible for surgery or percutaneous ablation, with 
tumor at stage BCLC B (Child-Pugh ≤ B8; PS < 2). HCC nodule >10 cm, macro-
scopic vascular invasion, extrahepatic disease, untreatable ascites, jaundice and 
kidney disfunction strongly contraindicate TACE [4, 5]. Potential adverse effects 
are liver enzyme abnormalities (18.1%), fever (17.2%), hematological/bone mar-
row toxicity (13.5%), pain (11%), vomiting (6%) and even death (0.6%) for liver 
failure [5].
RFA can be used as a complementary technique with TACE, to treat residual 
neoplastic tissue [22]. Patients with bigger nodules (>3 cm) and with capillary 
vascularization receive higher benefit from this combination [5, 23].
TARE is also called selective internal radiation therapy (SIRT). It is a pallia-
tive brachytherapy that uses radioactive substances (Y90-microspheres) injected 
into tumor-feeding arteries. This complex procedure is indicated in patients with 
conserved liver function (Child-Pugh ≤ 8, bilirubin ≤ 2.0 mg/dl, no ascites) and 
locally advanced HCC, not eligible for surgery or TACE (portal system invasion 
or unencapsulated large lesions). Pulmonary shunt and other vascular anomalies 
contraindicate to this technique [4, 5].
PEI induces tumor cell necrosis through dehydration, protein denaturation 
and small tumor vessel disruption. It is indicated in patients not eligible neither 
for resection nor for other forms of ablation, especially in HCC nodules ≤3 cm in 
the hepatic hilum area. The application of this procedure is restricted because it 
allows only an incomplete necrosis in lesions >3 cm and leads to high recurrence 
rate [5, 24].
Cryoablation induces tumor cell necrosis using recurring applications of freez-
ing temperature. Despite its good efficacy, this procedure is barely used because it is 
associated with high risk of life-threatening complications such as cryoshock, cold 
injury to adjacent organs and massive bleeding [25].
LA induces tissue necrosis through conversion of absorbed light (usually 
infrared) into heat. It can be used to treat up to five lesions, measuring ≤5 cm, 
located in the deep parenchyma and distant from the vessels, biliary ducts, bowel or 
diaphragm, when patients are not eligible for resection [26]. It is rarely used because 
of difficulties in the technique’s management [5].
Surgical and non-surgical treatments, and the possibility of combined approach, 
should be carefully evaluated aiming for a tailored therapy.
Follow-up is fundamental in HCC patients, both in cirrhotic and non-cirrhotic 
ones, in order to promptly identify possible recurrences and to treat them in the 
best way. Intrahepatic recurrences, far from previously treated lesions, are always 
possible and generated by chronic hepatopathy; therefore, lifelong surveillance is 
necessary [4, 27].
The aim of this chapter is to illustrate the state of the art in liver surgery to 
achieve the best treatment for patients suffering from hepatocellular carcinoma.
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2. Planning and timing surgery
2.1 Multidisciplinary evaluation
The multidisciplinary unit is a highly specialized and dedicated team, composed 
of hepatobiliary and transplants surgeons, hepatologists, radiologists, pathologists, 
oncologists, interventional radiologists and supportive care specialists (Figure 1) 
[28]. The aim of the unit is to discuss complex patients, developing the best possible 
care plan for every different case. First of all, liver status and disease shall always be 
evaluated and taken into account, assessing them according to Child-Pugh (CTP), 
MELD or MELD-Na scores [5, 14, 29]. CTP score seems to have a higher specific-
ity than MELD in patients undergoing resective surgery (Table 2) [13]. Other 
important factors are preoperative platelet count, INR and hepatic venous pressure 
gradient (HVPG) [5, 30]. Cirrhotic patients eligible for hepatic resection should 
have ideally HPVG < 10 mmHg and platelet count ≥100,000/ml [5].
In addition to Child-Pugh and MELD scores, in borderline liver function, 
indocyanine green kinetics and cholinesterase/bilirubin ratio are useful to improve 
patients selection [5].
Thanks to multidisciplinary discussions in international meetings, many HCC 
staging systems have been proposed during the years [31]. The Cancer of the Liver 
Italian Program (CLIP) score and Barcelona Clinic Liver Cancer (BCLC) staging 
classification are the most comprehensive and commonly used systems to stage 
HCC patients. They consider the liver status and function, physical status, cancer-
related symptoms and number and extension of lesions. Patients are classified in six 
stages (CLIP score) or five stages (BCLC), each linked with a specific survival rate 
and treatment algorithm (Table 3, Figure 2) [32].
According to BCLC criteria, liver resection is indicated in BCLC stage A 
patients only, but several studies show that it could provide long-term sur-
vival with reduced intraoperative mortality in selected BCLC stage B patients 
(Figure 3) [33–36]. Patients having singular large nodule (>5 cm) and/or lateral-
ized multinodular tumor and a very well-preserved liver function are considered 
Figure 1. 
Composition of liver multidisciplinary units. Source: Siddique et al. [28].
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resectable stage B patients [38]. In order to achieve a parenchyma-sparing surgery, 
these patients may benefit from combining surgery with intraoperative ablation 
(RF/MW) [39, 40].
2.2 US evaluation of liver disease
Ultrasonography (US) has a primary role in HCC screening. US sensitivity ranges 
from 63 (for small lesions) to 94%, whereas specificity from 52 to 98% [41–43].
US is highly operator-dependent. Machine quality, tumor size and localization, 
liver echotexture and abdomen characteristic influence the diagnostic accuracy of 
the exam [44].
Six-month US is relevant in detecting early-stage HCC in high-risk patients 
[45]. US detection of small HCC nodules in cirrhotic livers is arduous due to altered 
echotexture [46].
If combined with serum marker alpha-fetoprotein (AFP), it allows further 
unidentified lesions’ detection in 6–8% of the cases [47]. AFP alone is a weak 
screening test (Se 39–64%, Sp 76–91%, cut-off 20 mg/ml) [41], since high AFP 
levels could be also related to inflammatory status (exacerbation of underlying 
chronic liver disease or hepatitis), and it is not increased in about 20% of HCC 
Child-Pugh score
Parameters
Points
1 2 3
Serum bilirubin (mg/dl) 2.0 2-3 >3.0
Serum albumin (g/dl) >3.5 2.8-3.5 <2.8
Prothrombin time
Seconds prolonged
1-4 4-6 >6
Hepatic encephalopathy None Mild to moderate (grade1 or 2) Severe (grade 3 
or 4)
Ascites None Mild to moderate (diuretic responsive) Severe (grade 3 
or 4)
5–6 points Child-Pugh A
7–9 points Child-Pugh B
10–15 points Child-Pugh C
Table 2. 
Child-Pugh scoring system.
CLIP score
Parameters
Points
0 1 2
Tumor morphology Uninodular and 
extension ≤ 50%
Multinodular and 
extension ≤ 50%
Massive or extension 
> 50%
Child-Pugh score A B C
Alpha-fetoprotein <400 ng/ml ≥400 ng/ml —
Portal vein 
thrombosis
Absent Present —
Maida et al. [31].
Table 3. 
CLIP score evaluation system.
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cases, especially in early stages [41]. PIVKA-II is another serum marker still under 
evaluation in combination with US for screening purposes, even if not enough 
evidences have been published yet to justify its use [48].
US is useful to evaluate liver status while planning treatment and to identify 
possible contraindication to surgery, such as portal vein thrombosis [5].
Contrast-enhanced ultrasound (CEUS) uses gas microbubbles as a contrast 
agent that highlights lesions with well-represented vasculature. Due to pulmonary 
clearance, it is suitable for patients with reduced renal function or renal failure. It is 
repeatable, noninvasive and without risks [49].
Figure 2. 
BCLC staging. Galle et al. [5].
Figure 3. 
Modified indications in BCLC staging. Source: Torzilli et al. [35] and Bolondi et al. [37].
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Differently from US, CEUS is not indicated for screening but for characterizing 
known nodules. HCC is characterized by arterial-phase enhancement and low 
and later wash-out (after at least 60 seconds) on CEUS [50, 51]. It may differenti-
ate HCC from other nodules in cirrhotic liver and distinguish neoplastic portal 
vein thrombosis from a benignant one [49]. However CEUS does not detect small 
(<20 mm) and deep-located lesions, and it hardly discriminates between HCC and 
cholangiocarcinoma (CCC) [5, 45].
CEUS alone is not enough neither for diagnosis nor for staging of HCC, so it 
shall be considered as a second-line method in patients unfit either for contrast CT 
(due to chronic kidney disease) or MRI (due to possible vascular metallic devices or 
claustrophobia) [50].
2.3 CT evaluation
CT is a second-line imaging technique that enables a high diagnostic accuracy, 
if proper technique and contrast administration are applied. The CT appearance 
of HCC is extremely variable and depends on growth pattern (solitary, multifocal 
masses of infiltrating neoplasm), size and histologic composition [52].
Hepatocellular carcinoma (HCC) is most often hypoattenuating on unenhanced 
scan. After contrast agent injection, HCC is typically hypervascular during the 
arterial phase: small lesions show more homogeneous enhancement than larger 
neoplasms that are heterogeneous. During the portal venous phase, HCC becomes 
iso- to hypoattenuating to the surrounding liver. On delayed phase the tumors wash 
out more rapidly than the hepatic parenchyma [45].
Based on the guidelines, these diagnostic criteria are sufficient for a noninvasive 
diagnosis of HCC [5].
HCC could also present atypical findings such as hypervascular lesion without 
wash-out or hypovascular tumor: hypovascular nodules are not uncommon, and 
they usually represent early stages like dysplastic nodules with focal HCC or well-
differentiated small HCCs [53].
Perfusion CT (PCT) allows quantitative evaluation of tumor-related angiogen-
esis, tissue perfusion and segmental hepatic function. Higher radiation dose and 
lower resolution are the main limitations of this method [45].
CT with higher spatial resolution is fundamental in preoperative management: 
firstly, in detection of vascular or bile ducts anatomical variants and also in calcu-
lation of the future remnant liver (FRL) if a major resection is considered [54].
Evaluation of anatomical variation is critic while planning hepatic resections. 
Hepatic arterial anatomy variations are common (approximately 45%), and different 
hepatic venous anomalies, such as drainage of segment VIII into the middle hepatic 
vein, of segments V and VI directly into the inferior vena cava and of accessory 
middle hepatic vein directly into the inferior vena cava, can impact surgery. Also por-
tal vein variants and biliary anatomy variations should be carefully investigated [55].
The FRL is calculated by dedicated software that analysed the total liver volume, 
the tumour volume and the liver volume after surgical procedure. The FRL volume 
of 20–30% is the lowest limit for a safe resection in healthy livers, 40% in elderly, 
whereas in patients with diffuse liver disease, a volumetric evaluation shall be 
associated with FRL function assessment (e.g. indocyanine green retention test or 
liver maximum capacity test) [54, 56, 57].
2.4 MRI
MRI is superior to CT for the diagnosis of HCC [53].
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At MR imaging small HCCs have variable signal intensity on T1-weighted 
pre-contrast imaging: they commonly appear hypointense, but high signal intensity 
has been reported with a frequency ranging between 34 and 61%. On T2-weighted 
images, HCC is iso- to hyperintense to the surrounding liver parenchyma. Generally, 
hyperintense lesions on T1 and isointense in T2 are well-differentiated, due to the 
presence of fat and or glycoprotein; on the contrary lesions hypointense on T1 and 
hyper on T2 are moderately/poor differentiated. After contrast agent injection, HCC 
shows the same imaging patterns described on CT examination [45, 58].
The introduction in clinical practice of liver-specific contrast agents, superpara-
magnetic as well as paramagnetic, significantly improves the detection and charac-
terization of HCC, in particular for lesions between 1 and 2 cm. With paramagnetic 
contrast agents, the absence of functional hepatocytes, which is considered a sign 
of malignancy, is represented as a loss of signal intensity during the hepatobiliary 
phase. Nevertheless, fewer than 20% of well-differentiated and moderately differ-
entiated HCCs appear iso- or hyperintense on hepatobiliary phase images [45, 58].
HCC can rarely invade biliary ducts, both microscopically and macroscopically 
[59]. Incidence of biliary duct invasion ranges from 1.2 to 9%. It shall be carefully 
evaluated while staging patients, in order to choose the best treatment and to assess 
prognosis. Biliary invasion, in fact, is an independent adverse prognostic factor and 
is often linked to higher biological aggressiveness and portal vein invasion which 
make prognosis worse [60].
MR cholangiopancreatography (MRCP) is a noninvasive procedure aimed for 
evaluating the hepatobiliary and pancreatic systems. This method is helpful in 
assessing biliary invasion. Biliary duct tumor thrombus appears as an intraluminal 
soft tissue with arterial-phase enhancement on MRCP, and biliary ducts could be 
seen dilated because of obstructing tumor fragments [60].
Several studies have shown that biliary ducts invasion in HCC is not a contra-
indication to surgical resection, even in patients with obstructive jaundice caused 
by biliary tumor thrombus, as long as R0 resection can be achieved. If jaundice is 
present, biliary drainage should be performed preoperatively [59, 61–63].
MRI also enables the estimation of fat storage in the liver parenchyma: proton 
density fat fraction (PDFF) technique is a fast, accurate and easy-to-use MR modal-
ity that allows liver fat quantification [52].
2.5 Bioptic evaluation
Biopsy of hepatic lesions is an invasive procedure. Its use is restricted, as a typi-
cal pattern in one second-line imaging technique is enough to make an HCC diag-
nosis, according to the guidelines [64]. In performing liver biopsy, indeed, there 
is a high risk of bleeding, even higher if the patient has a bleeding disorder due to 
cirrhosis, and an established possibility of seeding along the needle tract. However, 
haemorrhagic risk can be reduced with infusion of fresh frozen plasma and plate-
lets before the procedure [51]. Subcapsular and extended tumor and ascites could 
compromise safe needle insertion too [46].
The procedure allows histological analysis, so it may be used when HCC has 
atypical growing pattern, so that there is a high suspicion of cholangiocarcinoma 
(CCC), considering that in such cases bioptic results will impact on therapeutic 
choice, changing it completely [51].
Furthermore liver parenchyma biopsy is currently the reference procedure 
for assessing and staging fibrosis and cirrhosis. Stages are classified according to 
METAVIR score, a histopathologic grading system. Hepatic biopsy has some impor-
tant limitations: it allows the evaluation of a sample, and not of the entire liver, and, 
above all, it is an invasive method that could cause minor (temporary pain in 20% 
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of cases) or major (bleeding, sepsis, pneumothorax and even death in 1.1% of cases) 
complications [65].
2.6 Intraoperative US
Intraoperative ultrasonography (IOUS) is fundamental while performing 
hepatic resections. It can give further information about lesions and parenchyma 
and can determine modifications both in tumor staging and in surgical manage-
ment as well [66].
IOUS and contrast-enhanced intraoperative ultrasound (CE-IOUS) have higher 
sensitivity compared to preoperative US and CEUS and allow better detection and 
characterization of small nodules [66].
Without these intraoperative procedures, surgical inspection and palpation can 
overlook up to 50% of preoperatively undetected lesions, especially those located in 
deep parenchyma and in cirrhotic liver [67].
Furthermore, IOUS became a mandatory tool in major hepatic surgery, as it allows 
visualizing of major vessels, assessing their location in relation to HCC lesion and 
delimiting resection area. It is also important to identify correct dissection planes and 
accurately define tumor extension, thus to achieve higher rates of R0 resections [67].
3. Surgical treatment
Surgical resection is the first-line treatment in non-cirrhotic and compensated 
cirrhotic livers [5]. The aim of surgery is to achieve R0 resection while preserving 
enough future remnant liver, in order to avoid postoperative liver failure [68]. 
Therefore, the most appropriate surgical technique is chosen according to principles 
of oncological radicality, safety and the least invasiveness [69], considering that 
HCC tends to be a recurrent disease (recurrence rate 40–70%), and so re-resection 
or noninvasive treatments are often needed [70].
Large nodules, major intrahepatic vessels invasion, portal branches and hepatic 
vein thrombosis do not contraindicate to surgery as soon as R0 resection can be 
achieved [71], keeping in mind that a well-preserved liver function is necessary to 
perform radical hepatic resections [72]. Surgery can be even performed in case of 
HCV and HBV hepatitis as long as there is metabolic syndrome-related hepatopathy 
or cirrhosis is compensated. (Child-Pugh ≤ 8; MELD ≤ 9) [73].
Patient performance status is also a factor that has to be considered while 
planning a surgical resection of the liver. Advanced age is not a contraindication, as 
long as these patients are carefully selected, according to their general condition, 
performance status, life expectancy and treatment tolerability [56].
In some cases, surgery may be a bridging treatment to liver transplant in patients 
with advanced cirrhosis and HCC, when waiting time exceeds 6–8 months [74].
Impaired liver function, insufficient future remnant liver, advanced tumor stage 
and poor performance status are absolute contraindications to surgical resection 
[73]. Liver resection could not be performed in the case of Child-Pugh > 8,  
MELD ≥ 9, bilirubin ≥ 3 mg/dl associated with INR ≥ 1.7 or PT < 50%, platelet 
count < 50,000/μl, indocyanine green retention at 15 minutes >22% and portal vein 
pressure gradient >10 mmHg without possible TIPS [72, 73]. Extended portal or 
vena caval thrombosis and extrahepatic disease reveal an advanced HCC stage and 
contraindicate surgical resection [73]. Patients not eligible for surgery are those 
with ECOG performance status 4, ASA index > 3, Charlson’s index > 3–4 and older 
than 70 years with comprehensive geriatric assessment (CGA) = 3 or systemic 
diseases with severe prognosis (life expectancy < 12 months) [56].
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Intrahepatic recurrence after surgical treatment is often linked to portal venous 
invasion, both macroscopic (MPVI) and microscopic (mPVI). MPVI can be preop-
eratively detected by CT, MRI and US, whereas mPVI is very difficult to diagnose 
preoperatively. In order to reduce recurrence rates due to mPVI, in young and fit 
patients, anatomic liver resection (ALR) should be preferred to nonanatomic liver 
resection (NALR) [75]. ALR should be taken into account especially in patients who 
have solitary PVI (in a single portal vein branch) or a higher risk of mPVI linked to 
α-fetoprotein ≥ 20 ng/ml, PIVKA-II ≥ 100 mAU/ml, tumor size ≥ 5 cm and a conflu-
ent lesion morphology [76, 77]. Some authors suggest that during anatomic resec-
tion, it is better to avoid excessive rotation of the liver, perform an early extrahepatic 
ligation of the portal pedicle of the resected segment(s) before parenchymal transec-
tion and obtain an adequate surgical margin to decrease the risk of recurrences [71].
On the other hand, NALR allows parenchyma-sparing surgery that, though 
associated to higher recurrence rates, is indicated in elderly and cirrhotic patients 
suffering from early HCC, where an anatomic resection would sacrifice an excessive 
amount of the parenchyma (Figure 4) [75].
Surgery is proved to be superior to RF in terms of local recurrences for nodules 
>2 cm [19, 78], but in the case of multinodular HCC, in selected patients, they can 
be combined together to achieve a better outcome, compared to TACE or TARE, 
whose role remains palliative (Figure 5) [35, 64, 78].
3.1 Major hepatectomies
All liver resections involving three or more liver segments of Couinaud are 
considered major hepatectomies. Most commonly performed resections are right 
hepatectomy, left hepatectomy, right-extended hepatectomy, left-extended hepa-
tectomy and median hepatectomy [69]. Major hepatectomy is frequently required to 
achieve a complete tumor removal (Figure 6) [79].
Healthy livers may be resected as much as 70% without major complications; 
cirrhotic or hepatopathic patients shall be cautiously submitted to resection after 
precise FRL analysis in terms of future remnant liver function (FRLF) and volume 
[54]. Liver resections for HCC related to NAFLD and metabolic syndrome are 
encumbered by important rates of complications (13–20%) and mortality (2%); 
procedure risk profile in this condition is closer to that burdening cirrhotic livers 
rather than non-cirrhotic ones [5].
Age is not a contraindication to major hepatectomy, because elderly patients’ 
liver, when healthy, have comparable regeneration rates to younger ones, while 
patients’ performance status and liver residual function are more important [80].
Major hepatectomies can be performed safely in either open or mini-invasive 
approaches [81].
Open approach is more invasive, but it offers great advantages in a better view on 
the operative field, allowing a complete administration in organ mobilization and 
a prompt control of bleeding (Figure 7). Open approach is indicated in the case of 
upper abdominal adhesions, respiratory impairment and advanced liver fibrosis. In 
severe respiratory disease, pneumoperitoneum worsens gas exchange; therefore, lapa-
roscopic- and robot-assisted resection are contraindicated [82]. In the case of upper 
abdominal adhesions, it is hard to induce an adequate pneumoperitoneum to insert 
trocars and instrument safely, and open approach is the one indicated [83]. Advanced 
liver fibrosis makes the organ stiffer and difficult to mobilize with laparoscopic grasp-
ers [84]. The liver hanging manoeuver (LHM), which is a technique of passing a tape 
along the retrohepatic avascular space and suspending the liver during parenchymal 
transection, facilitates anterior approach of major hepatectomy and minimizes bleed-
ing by elevation of the liver along its deeper parenchymal plane [85, 86].
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Figure 4. 
Wedge resection (NALR) in the NAFLD liver. HHC located in V/VIII segment.
Figure 5. 
Intraoperative RF in HCC nodule of II segment.
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Figure 7. 
(A) Dissection of liver hilum. Elements are indicated by arrows: choledocus (green), portal vein (blue), 
hepatic artery (black). (B) Caval detachment in bisegmentectomy (VI–VII).
Minimally invasive liver surgery has strongly progressed during the last 20  
years [87].
Laparoscopic approach is proven as being safe and presents good outcomes in 
terms of hospitalization and morbidity. However, the main disadvantage of this 
approach is the lack of control when a huge bleeding occurs, but the LHM reducing 
bleeding risk makes the procedure safer.
Robotic-assisted resection is the newest technology in hepatobiliary surgery. 
Compared to laparoscopy, robotic instruments allow wide-angle rotation; therefore, 
it is easier and faster to perform sutures and ligatures. Four-arm da Vinci Si enables 
the surgeon to perform safer resections, reduced bleeding and major dexterity, 
particularly in hilar time and in vena cava detachment time. One of the major 
disadvantages of the robot is its cost [88, 89].
HCC is a fast-spreading tumor, particularly in the vascular system; therefore, 
major resections in large or multinodular tumors allow the most radical removal; 
however, consistent volume of the functioning liver is also resected, increasing risks 
of liver impairment in cirrhotic and hepatopathic patients [90].
Figure 6. 
(A) Large HCC In non-cirrhotic live requiring right hepatectomy. (B) Extended right hepatectomy in 
NAFLD, surgical sample showing a 11-cm HCC.
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3.2 Limited hepatectomies
Limited hepatectomy means resection of two or less segments of Couinaud, like 
left lobectomy, involving segments II and III, and bisegmentectomy of VI–VII and 
VI–V, that are the most common (Figure 8). Limited hepatectomies are indicated in 
the case of single or multiple HCC nodules located in one or two adjacent liver seg-
ments [69], especially when early diagnosed. Otherwise non-followed up patients 
are often diagnosed with advanced or multinodular HCC, which are eligible to more 
extended hepatectomies only.
Limited hepatectomies tend to preserve liver function, so analysis of FRLF and 
FRLV is often unnecessary in healthy patients, while it is mandatory in compen-
sated cirrhosis due to higher resection risk and distorted liver anatomy [73].
Limited resection is often performed with mini-invasive surgical technique, 
such as laparoscopic- or robot-assisted surgery. Although expert surgeons are able 
to resect safely even posterior and subdiaphragmatic lesions, these techniques have 
some limits. Laparoscopy, in fact, has prolonged surgical times for liver mobiliza-
tion due to difficulties in parenchyma manipulation, arduous bleeding control and 
necessity of a major experience of the surgeon.
Robotic liver resection (RLR) allows to go beyond laparoscopic disadvantages, 
thanks to superior flexibility of its arms. For this reason, RLRs are considered 
safe, even in deep parenchyma or posterior segment [89]. It is comparable to 
open approach considering the oncological radicality, but it presents the same 
advantages of laparoscopy in terms of length of hospital stay and postoperative 
complications. Conversion rate from robotic to open approach ranges from 0 to 
8.8% [87].
Open surgery shall be chosen in the case of contraindications to other 
approaches such as respiratory impairment that is worsened by pneumoperitoneum 
or excessive difficulties in liver manipulation; the surgeon’s experience remains an 
important variable in surgical indications, and safety of intervention shall always 
drive the choice [82, 84].
Nonanatomic liver resection, or wedge resection, is reserved for early HCC 
(BCLC 0 or A), particularly in the elderly, suffering from advanced cirrhosis or 
exophytic lesions in hypertrophic segments, where anatomic resection would 
determine too extensive healthy parenchyma loss [75].
Figure 8. 
Anatomic resection of segment VI in cirrhotic live. HCC diameter 2.5 cm.
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3.3 Staged hepatectomies
Staged hepatectomies in HCC treatment are the most recent innovation, first 
introduced to treat multiple colorectal metastases, now under evaluation for 
extended hepatectomies in advanced HCC patients [91]. The main issue related to 
this technique is that most HCC patients are cirrhotic or hepatopathics, and cirrho-
sis limits parenchyma regeneration in a significant way [91, 92].
Extended resection is feasible when the future remnant liver is ≥40% for cir-
rhotic patients, ≥30% in patients with severe steatosis or fibrosis without cirrhosis 
and ≥20% in those with normal liver function [93].
Several strategies can be carried out in order to increase future remnant liver 
volume (FRLV), improve resectability and reduce postoperative risk of liver failure 
(PLF) in patients with inadequate FRLV. These techniques include preoperative 
portal vein embolization (PVE) or ligation (PVL), sequential transarterial chemo-
embolization and PVE, two-stage hepatectomy (TSH), preoperative Yttrium-90 
(90Y) radioembolization (RE) and associated liver partition and portal vein ligation 
for staged hepatectomy (ALPPS) [93]. Parenchyma hypertrophy shall be assessed 
using CT volumetry before performing second-stage hepatectomy [94].
ALPPS is indicated in non-cirrhotic patients with insufficient remnant liver 
or in the case of PVE failure [93, 95, 96]. This procedure allows higher and faster 
hypertrophy rates compared to other strategies, due to parenchyma transection and 
collateral portal branches ligation, especially in hepatopathics; such advantages have 
been seen also in cirrhotic patients [92]. Moreover, it reduces risk of HCC progres-
sion thanks to the shorter time interval between operations. On the other hand, it 
is associated with high risk of PLF (27%) probably due to portal hyperperfusion, 
major perioperative complications and mortality [97]. Some authors suggest that the 
use of anterior approach combined with hanging manoeuver allows higher control 
and safety during ALPPS procedure [92]. Only few case series have been published 
about staged hepatectomy for HCC, more perspective research is still necessary, 
even if this technique is proofing effective and beneficial in selected patients [98].
3.4 Complication
Postoperative complications have higher incidence and severity in cirrhotic 
patients [99].
Postoperative live failure (PLF) is the most life-threatening complication fol-
lowing hepatic resection, especially in cirrhotics [93]. It is defined as the decrease 
in liver synthetic, excretory and/or detoxifying functions after resection [100]. It 
can be associated with insufficient future liver volume, prolonged operative time, 
prolonged ischemia, massive intra- and postoperative bleeding, hemodynamic 
instability, bile duct obstruction, drug-induced injury, viral reactivation and sepsis 
[90]. It occurs after the fifth day in 4–19% of cases, and it is characterized by vari-
ous symptoms and signs, such as ascites, pleural effusion, prolonged cholestasis, 
coagulation disorders, elevated serum lactate levels, hyperbilirubinemia, hypoalbu-
minemia, hypoglycaemia and hepatic encephalopathy [90, 93].
Bile leakage is another severe postoperative complication. It occurs in 4–17% of 
cases with comparable incidences in laparoscopic and open approaches [101]. It can 
induce further complications, such as extrahepatic abscess, requiring reoperation; 
otherwise it is usually managed with interventional radiology [100].
Postoperative ascites is common, and it may be caused by portal flow resistance 
increase and serum albumin loss. It can be treated with diuretics, sodium restriction 
or albumin infusion [100]. Persistent ascites is associated to higher risks of sponta-
neous bacterial peritonitis (SBP) and mortality.
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Clotting disorders are frequent after extended hepatectomies and in cirrhotic 
patients, who may already have preoperative low platelet count. They can manifest 
as PT and aPTT prolongation, increase in levels of fibrinogen degradation products 
and platelet levels reduction [100].
Surgical site infection may occurs within 30 days after resection [100].
Postoperative pneumonia and respiratory disturbs (acute lung injury, acute 
respiratory distress syndrome) rarely occur after liver resection, especially in the 
elderly [100].
Resected patients shall be rapidly mobilized postoperatively; feeding shall 
start early, together with intravenous liquid restriction. Nonadequately selected 
patients may also suffer from postoperative acute renal failure or hepatorenal 
syndrome [100].
Mini-invasive surgical approaches allow lower postoperative complications, such 
as ascites, pleural effusion and hospital-acquired infections [87, 99, 102].
4. Follow-up
HCC recurrence within 5 years after hepatic resection occurs in 40–70% of 
patients [70, 103, 104]. Several recurrence risk factors should be carefully consid-
ered while planning postoperative surveillance (Table 4) [70].
Intrahepatic recurrent HCC can develop from an intrahepatic metastasis (IM 
type) or arise from de novo multicentric carcinogenesis (MO type) due to the 
underlying chronic liver disease. These two HCC types can be distinguished accord-
ing to their clinic-pathological characteristics and recurrence-free interval [70].
Early recurrence occurs within 2 years from primary resection, and they seem 
associated with intrahepatic metastasis, whereas late recurrences can show up more 
than 2 years after surgery, and they are linked to multicentric occurrence [105].
Differentiating them is important because MO, compared to IM, is associated 
with higher survival rate after repeated resection and better prognosis [106].
RHCCs have the same imaging features of primary HCC, so they shall be 
detected and diagnosed using the same methods of primary HCC diagnosis.
US, CT or MRI and AFP determination should be performed after surgical 
resection.
Surgical factors Non-anatomical resection
Positive histologic margin (R1 or R2)
Necessity of transfusion due to significant bleeding
Iatrogenic tumor escape or rupture
Clinicopathological factors Low tumor differentiation
Advanced tumor stage
Tumor rupture, damaged capsule
Tumor diameter > 5 cm
Tumor number ≥ 3
Vascular tumor thrombus
Lymph node invasion
Adjacent organ invasion satellite lesion
High level of AFP before operation
Increased AFP level 2 months after operation
Patient’s factor Underlying chronic liver disease: active hepatitis infection or cirrhosis
Wen et al. [70].
Table 4. 
Risk factors of postoperative recurrence.
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US should be performed every 6 months within the first 5 years after surgical 
treatment; a second level imaging study is requested at the first year and repeated 
after 12–18 months according to the underlying liver status [5]. Resected patients 
for HCC, who received direct-acting antiviral (DAA) therapy for HCV negativiza-
tion, are commonly kept in a less intensive follow-up with US every 12–18 months, 
for a persistent recurrence risk is maintained [107].
Once detected, RHCC shall be carefully assessed in order to plan the best 
therapy. Re-resection is the treatment of choice if nodule is resectable and patient is 
eligible for surgery; so, disease-free time, performance status, future remnant liver 
volume and function, cirrhosis, portal hypertension and other aspects should be 
evaluated again before repeating operation. Only about 20% of patients with recur-
rent HCC receive surgical treatment [105]. Multiple resections could be performed 
after major or limited primary hepatectomy [70, 108].
Both open and laparoscopic resections can be carried out, but laparotomy is 
generally preferred, since intra-abdominal adhesions limit laparoscopic approach 
[109]. Five-year survival rate higher than 70% can be achieved in well-selected 
patients, despite repeated treatments [103, 104].
Prognosis after repeated resections is linked to clinic-pathological characteristics 
of primary HCC and recurrence interval. Particularly a disease-free period longer 
than 1 year after primary resection, single primary HCC and negative portal inva-
sion are positive prognostic factors after second resection [105, 108].
Other possible locoregional therapies for recurrent illness are RFA, MWA and 
TACE. Liver transplantation could be taken into account in selected patients with 
worsened liver function and falling within transplant criteria [70, 103].
Incidence of extrahepatic metastases (EHM) after hepatectomy is low (range 
5–20%) [108, 110]. High-serum alpha-fetoprotein levels, after liver resection or 
transplant, is suspicious for extrahepatic recurrence; thus serial cross-sectional 
total body imaging is mandatory to identify them, and palliative R0 resection may 
be performed in fit patients with quality of life and survival benefits [27].
5. Conclusion
HCC is a deadly malignancy either in cirrhotic and non-cirrhotic patients. 
A well-timed follow-up and detection of patients at risk are fundamental, since 
diagnosis at early stage allows more aggressive and effective treatments. HCC in 
non-cirrhotic liver will be more often diagnosed, particularly in the case of NASH 
and NAFLD, because they are followed up more strictly.
In recent years, indications to surgery have not changed substantially, while a lot 
has been introduced in terms of imaging, which is nowadays an essential support 
in preoperative planning, intraoperative guide and postoperative follow-up. Staged 
hepatectomy techniques have shown interesting results and will become part of 
clinical practice in the future, especially in treatment of non-cirrhotic patients. 
Surgery remains the most effective treatment against HCC, since complete resec-
tions allow important survival benefits at 3, 5 and 10 years.
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